SAILIFE vs WINDLAS: Stock Comparison
Sai Life Sciences Limited is the larger company by market capitalisation. Sai Life Sciences Limited shows a higher ROE, a higher ROCE and a higher net margin, while Windlas Biotech Ltd shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SAILIFE leads 6; WINDLAS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SAILIFE | WINDLAS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SAILIFE | WINDLAS |
|---|---|---|
| Live Price | ₹1,457.4 | ₹993.6 |
| Day Change | -0.96% | 0.55% |
| Volume | 3.24 L | 1.73 L |
| 52-Week High | ₹1,484.2 | ₹1,045.45 |
| 52-Week Low | ₹783.85 | ₹697.4 |
| Distance from 52W High | -1.81% | -4.96% |
Valuation
| Metric | SAILIFE | WINDLAS |
|---|---|---|
| Market Cap | ₹30,979 Cr | ₹2,050 Cr |
| P/E Ratio | 84.93x | 42.91x |
| P/B Ratio | 12.4x | 3.61x |
| EPS | ₹16.43 | ₹31.5 |
| Book Value | ₹117.47 | ₹275 |
| Dividend Yield | 0% | 0.63% |
Growth
| Metric | SAILIFE | WINDLAS |
|---|---|---|
| Revenue Growth (TTM YoY) | 3.9% | 17.7% |
| EPS Growth (TTM YoY) | 17.6% | -2.6% |
| Qtr Sales Growth | 3.91% | 17.7% |
| Qtr Profit Growth | 17.8% | -1.78% |
Profitability & Leverage
| Metric | SAILIFE | WINDLAS |
|---|---|---|
| ROE | 15.4% | 12.2% |
| ROCE | 19.6% | 15.9% |
| Net Margin | 15.81% | 7.35% |
| Operating Margin | 28.8% | 11.6% |
| Debt to Equity | 0.12x | 0.06x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | SAILIFE | WINDLAS |
|---|---|---|
| Promoter Holding | 32.87%▼ 0.08 pp | 63.31%▲ 1.41 pp |
| FII Holding | 19.65%▼ 1.52 pp | 2.04%▲ 1.44 pp |
| DII Holding | 32.71%▲ 1.17 pp | 9.84%▼ 1.97 pp |
| Public Holding | 13.11%▲ 0.43 pp | 24.8%▼ 0.9 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Sai Life Sciences Limited and Windlas Biotech Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.